CLINICAL TRIALS PROFILE FOR MICARDIS HCT
✉ Email this page to a colleague
All Clinical Trials for MICARDIS HCT
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00034840 ↗ | Telmisartan vs. Valsartan in Patients With Mild to Moderate Hypertension Following a Missed Dose | Completed | Bayer | Phase 4 | 2001-10-01 | The primary objectives are to demonstrate that MICARDIS® (telmisartan) is statistically superior to Diovan® (valsartan) in reducing diastolic blood pressure (DBP) following a missed dose at the end of a 6 to 8-week treatment period as measured by the 24-hour ABPM mean and to demonstrate that MICARDIS® is statistically superior to Diovan® in reducing DBP during the last 6-hours of the 24-hour dosing interval as measured by ABPM following a dose of active study medication at the end of a 6 to 8-week treatment period. |
NCT00034840 ↗ | Telmisartan vs. Valsartan in Patients With Mild to Moderate Hypertension Following a Missed Dose | Completed | GlaxoSmithKline | Phase 4 | 2001-10-01 | The primary objectives are to demonstrate that MICARDIS® (telmisartan) is statistically superior to Diovan® (valsartan) in reducing diastolic blood pressure (DBP) following a missed dose at the end of a 6 to 8-week treatment period as measured by the 24-hour ABPM mean and to demonstrate that MICARDIS® is statistically superior to Diovan® in reducing DBP during the last 6-hours of the 24-hour dosing interval as measured by ABPM following a dose of active study medication at the end of a 6 to 8-week treatment period. |
NCT00034840 ↗ | Telmisartan vs. Valsartan in Patients With Mild to Moderate Hypertension Following a Missed Dose | Completed | Boehringer Ingelheim | Phase 4 | 2001-10-01 | The primary objectives are to demonstrate that MICARDIS® (telmisartan) is statistically superior to Diovan® (valsartan) in reducing diastolic blood pressure (DBP) following a missed dose at the end of a 6 to 8-week treatment period as measured by the 24-hour ABPM mean and to demonstrate that MICARDIS® is statistically superior to Diovan® in reducing DBP during the last 6-hours of the 24-hour dosing interval as measured by ABPM following a dose of active study medication at the end of a 6 to 8-week treatment period. |
NCT00133185 ↗ | A Randomized, Double-blind, Parallel-group Assessment of the Safety and Efficacy of Telmisartan 40mg Plus Hydrochlorothiazide 12.5mg (Micardis Plus) in Comparison With Losartan 50mg Plus Hydrochlorothiazide 12.5mg in Taiwanese Patients With Mild to | Completed | Boehringer Ingelheim | Phase 3 | 2004-03-01 | The primary objective of this trial is to compare the efficacy and safety of telmisartan 40 mg/hydrochlorothiazide 12.5mg (Micardis Plus) with that of losartan 50 mg/hydrochlorothiazide 12.5 mg, a reference AIIA combined with diuretic, in Taiwanese patients with mild to moderate hypertension. |
NCT00144222 ↗ | Combination of Telmisartan 40 mg Plus Hydrochlorothiazide (HCTZ) 12.5 mg vs. Telmisartan 40 mg Alone in Patients With Essential Hypertension Who Fail to Respond Adequately to Telmisartan Monotherapy | Completed | Boehringer Ingelheim | Phase 3 | 2005-01-01 | The objective of this trial is to demonstrate that the fixed dose combination of telmisartan 40 mg and HCTZ 12.5 mg is superior to the monocomponent of telmisartan (Micardis, Gliosartan, Kinzal, Kinzalmono, Predxal, Pritor, Samertan, Telmisartan) 40 mg in patients with essential hypertension who fail to respond adequately to telmisartan monotherapy. |
NCT00146289 ↗ | The Primary Objective of This Study is to Determine Whether MICARDIS® Improves Insulin Sensitivity in Overweight or Obese, Non-diabetic, Normotensive Subjects | Completed | Boehringer Ingelheim | Phase 2 | 2005-02-01 | The primary objective of this study is to determine whether MICARDIS® improves insulin sensitivity in overweight or obese, non-diabetic, normotensive subjects. |
NCT00147264 ↗ | Telmisartan-Induced Reduction in Intra-Myocellular Lipids Trial | Completed | Boehringer Ingelheim | Phase 3 | 2004-04-01 | The purpose of this study is to determine whether telmisartan and/or a low-glycemic index diet are effective in reducing intra-myocellular lipid (muscle fat) content. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for MICARDIS HCT
Condition Name
Clinical Trial Locations for MICARDIS HCT
Trials by Country
Clinical Trial Progress for MICARDIS HCT
Clinical Trial Phase
Clinical Trial Sponsors for MICARDIS HCT
Sponsor Name